First AD

Second AD

Tafasitamab and Lenalidomide for R/R DLBCL

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Hematologic Oncology

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

New Treatment Options for DLBCL: Impact on Sequencing Therapeutic Choices

Peer Exchange

A comprehensive overview of tafasitamab plus lenalidomide for patients with relapsed/refractory DLBCL, highlighting data updates and the impact on clinical practice.

Overview of First-Line Treatment in Diffuse Large B-Cell Lymphoma

Evolving Practice Standards and Disease Progression Beyond Frontline Therapy for Patients with DLBCL

Treatment Selection in Second Line R/R DLBCL

Real-World Outcomes of Tafasitamab-Lenalidomide for Patients with R/R DLBCL

The Role of CAR T-Cell Therapy in R/R DLBCL

Data Updates: CAR T in the ZUMA-7 and TRANSFORM Trials for R/R DLBCL

Clinical Perspectives of CAR T in R/R Diffuse Large B-Cell Lymphoma

Navigating Toxicities in CAR T-Cell Therapy in R/R DLBCL

Relapsed/Refractory DLBCL: Therapeutic Options in the Third Line Setting

Bispecifics for Third Line Therapy of R/R DLBCL

R/R DLBCL: Safety Considerations for Bispecific Antibodies

Treatment Sequencing of Later Line Therapies in R/R DLBCL

Additional Data Updates from ASH 2023

Future Outlooks in the Treatment of R/R DLBCL